Fibrocytes in Scleroderma Lung Fibrosis by Ronald Reilkoff et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
Fibrocytes in Scleroderma Lung Fibrosis 
Ronald Reilkoff, Aditi Mathur and Erica Herzog 
Yale University School of Medicine 
United States 
1. Introduction 
Systemic sclerosis (SSc) or “Scleroderma” is a disease characterized by cutaneous and 
visceral fibrosis that affects both the skin and internal organs. The worldwide prevalence 
ranges from 50-300 cases per million (Chifflot et al., 2008) and much of the morbidity in this 
population results from pulmonary complications. In fact, nearly 70% of scleroderma 
patients show some form of lung disease. Of the two forms of lung involvement, pulmonary 
arterial hypertension and interstitial lung disease, the latter has emerged as the greatest 
cause of death in these patients. The lungs of patients with scleroderma associated 
interstitial lung disease (SSc-ILD) exhibit replacement of the normal lung architecture with 
inflamed and fibrotic tissue that cannot participate in gas exchange. While approximately 
42% of patients with SSc-ILD die of disease progression within ten years of diagnosis (Steen 
& Medsger, 2007) evidence is emerging that some patients progress slowly and in some 
cases spontaneously improve while others follow an accelerated clinical course (Goh et al., 
2008). There is currently no way to predict which patients will progress rapidly and require 
more intensive therapy (Daoussis et al., 2010 ; Swigris et al., 2006; Tashkin et al., 2006) 
and/or referral for lung transplantation (D'Ovidio et al., 2005a; D'Ovidio et al., 2005b); and 
which patients will follow a more indolent course requiring less intense follow up. 
Therefore the development of a clinically predictive measure of pathologic progression 
would benefit physicians caring for patients with this disease. The ideal biomarker would be 
present in easily accessible clinical specimens, would be a potential contributor to disease 
development, and would be easily studied in murine models of disease. For this reason, 
peripheral blood fibrocytes have emerged as an exciting new area of study in the field of 
Scleroderma (Gan et al., 2011; Mathai et al., 2010; Peng et al., 2011 ; Tourkina et al.,2011; 
Reilkoff et al., 2011). 
2. Fibrocytes 
Fibrocytes are blood borne collagen-producing cells that were initially described in 1994. 
Since then, they have been associated with a broad range of fibrosing disorders including 
autoimmune illnesses and chronic inflammatory diseases. In some of these diseases, high 
circulating levels correlate with poor outcomes. In addition to extracellular matrix (ECM) 
synthesis, fibrocytes display other functions including antigen presentation and the 
secretion of pro-fibrotic and pro-angiogenic factors. 
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2.1 Disease associations 
Identified by their co-expression of leukocyte markers such as CD45, extracellular matrix 
proteins such as Collagen-1ǂ and in some cases markers expressed by progenitor cells such 
as CD34 (Bucala et al., 1994), fibrocytes are easily detected via flow cytometric and in vitro 
culture techniques. These approaches demonstrate that abnormalities in peripheral blood 
fibrocytes exist in diverse forms of autoimmune disease such as rheumatoid arthritis 
(Galligan et al., 2010), autoimmune thyroiditis (Douglas et al., 2009), amyopathic 
antisynthetase syndrome (Peng et al., 2011), and scleroderma (Gan et al., 2011 ; Mathai et al., 
2010). Elevations in peripheral blood fibrocytes are seen in chronic inflammatory disorders 
not traditionally associated with autoimmunity such as idiopathic pulmonary fibrosis 
(Mehrad et al., 2007; Mehrad et al., 2009; Moeller et al., 2009), asthma (Schmidt et al., 2003; 
Nihlberg et al., 2006; Wang et al., 2008), nephrogenic systemic fibrosis (Vakil et al., 2009), 
cardiovascular disease (Falk, 2006), pulmonary hypertension (Nikam et al., 2011), and even 
normal aging (Mathai et al., 2010). Thus it is not surprising that the role fibrocytes play in 
tissue repair and remodeling is a developing area of interest in the study of fibrosis and 
autoimmunity. 
2.2 Identification of fibrocytes in the circulation 
Flow cytometry identifies fibrocytes from the circulation or tissue using the combination of 
characteristic cell surface marker expression with intracellular staining for collagens or 
extracellular matrix components. Human fibrocytes express hematopoietic markers such as 
CD45 (Bucala et al., 1994), Leukocyte specific protein-1 (Yang et al., 2002), as well as markers 
of adhesion and motility (Pilling et al., 2009), chemokine receptors such as CXCR4 (Mehrad 
et al., 2007), proteins important in host defense and scavenger receptors (Pilling et al., 2009), 
antigen presentation (Chesney et al., 1997), and cell surface enzymes such as CD10 and 
CD13 (Pilling et al., 2009). Fibrocytes typically lack markers of lymphocytes (Bellini & 
Mattoli, 2007; Pilling et al., 2009). Circulating and cultured fibrocytes also express CD34 
(Bucala et al., 1994), a motility protein that allows fibrocytes to be distinguished from other 
collagen-containing cell types such as fibroblasts and macrophages (Reilkoff et al., 2011). 
However, because CD34 is frequently lost upon entry into target tissue (Peng et al., 2011; 
Phillips et al., 2004) its absence does not rule out a cell as being a fibrocyte. Fibrocytes also 
produce a wide array of ECM components (Bianchetti et al., 2011; Bellini & Mattoli, 2007; 
Pilling et al., 2009). A listing of fibrocyte markers is shown in Table 1. 
2.3 Differentiation and homing 
Insight into potential fibrocyte functions may be gleaned from an understanding of the 
factors promoting their differentiation and recruitment. Fibrocytes differentiate from a 
precursor population within the CD14+ monocyte fraction of peripheral blood (Abe et al., 
2001). The monocyte to fibrocyte transition, which is increased by enrichment for CD11b(+) 
CD115(+) Gr1(+) expressing monocytes, is promoted by direct contact with activated CD4+ 
lymphocytes via an mTOR-PI3 kinase dependent pathway (Niedermeier et al., 2009). Other 
studies have determined that the fibrocyte precursor expresses components of the FcǄ 
receptor (Pilling et al., 2003). Inhibition of this receptor with the short pentraxin protein 
serum Amyloid P reduces fibrocyte outgrowth in human (Pilling et al., 2003; Pilling et al., 
2006) and rodent samples (Murray et al., 2011; Pilling et al., 2007). This effect appears to be 
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mediated via an ITIM-dependent mechanism (Castano et al., 2009). The monocyte to 
fibrocyte transition is inhibited by exposure to TH1 cytokines (IFNǄ, TNF, and IL-12); and is 
augmented by TH2 cytokines (IL-4 and IL-13) (Shao et al., 2008). Fibrocyte differentiation is 
further stimulated by TGF-ǃ1, and via engagement of the ǃ1 integrin subunit (Bianchetti et 
al., 2011 ; Gan et al., 2011 ; Nikam et al., 2011). 
Murine modeling demonstrates that certain chemokine receptors such as CCR2, CCR7, and 
CXCR4 promote fibrocyte recruitment to diseased tissue (Phillips et al., 2004; Moore et al., 
2006; Sakai et al., 2006). Thus it is particularly relevant that human fibrocytes express the 
chemokine receptors CCR3 (eotaxin receptor) and CCR5 (MCP-1 receptor). Human 
fibrocytes also express Semaphorin 7a (Quan et al., 2004), a GPI-anchored membrane protein 
with important immunomodulatory effects (Czopik et al., 2006; Suzuki et al., 2007). Our 
own work in scleroderma patients demonstrates an association between fibrocytes serum 
concentrations of soluble factors such as TNF, IL-10, MCP-1 and IL-1 receptor antagonist 
(IL-1Ra), suggesting that fibrocytes may be mobilized into the circulation in response to one 
or more of these factors. Similarly, idiopathic pulmonary fibrosis (IPF) patients demonstrate 
high levels of CXCL12 in their blood and lungs, which is the cognate ligand for CXCR4, and 
these levels correlate with circulating fibrocyte concentrations (Mehrad et al., 2007). When 
viewed in combination, this array of stimulatory factors suggests that fibrocytes are 
recruited to injured tissue where they may play a role in the healing processes by via both 
immunomodulatory and ECM-producing effects. 
2.4 Immunologic function 
One school of thought posits that the ultimate phenotype of fibrocytes is the activated 
myofibroblast (Abe et al., 2001; Phillips et al., 2004; Quan et al., 2004; Gomperts & Strieter, 
2007). This hypothesis is based on several studies demonstrating cultured fibrocytes 
respond to TGF-ǃ1 by expressing ǂ-SMA and contracting collagen gels in vitro (Abe et al., 
2001; Phillips et al., 2004; Quan et al., 2004; Gomperts & Strieter, 2007). However, because in 
vivo studies using bone marrow chimeras show only minimal contributions of fibrocytes to 
ǂ-SMA production in some models (Hashimoto et al., 2004; Kisseleva et al., 2006; Lin et al., 
2008), this feature of fibrocytes may not dominate in tissue remodeling responses. When 
viewed in this light, it is particularly important to examine the immunomodulatory 
functions that fibrocytes are known to possess. 
 
Type of Marker Level of Expression Reference 
Adhesion and Motility   
CD9, CD11a, CD11b, CD11c, CD43, 
CD164, Mac2, LSP-1 
Moderate 
(Galligan et al., 2011; 
Bucala et al., 1994; 
Yang et al., 2002; 
Pilling et al., 2009) 
CD34 Low 
(Mathai et al., 2010; 
Bucala et al., 1994; 
Barth et al., 2002) 
CD29, CD44, CD81, ICAM-1, CD49 
complex, CD81 
Low 
(Mathai et al., 2010; 
Nikam et al., 2011; 
Bucala et al., 1994; 
Pilling et al., 2009) 
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Type of Marker Level of Expression Reference 
Cell Surface Enzymes   
CD10, CD172a Low (Bucala et al., 1994) 
CD13, Prolyl-4-hydroxylase Low  
FAP Low  
Scavenging receptors and host defense   
CD14, CD68, CD163, CD206, 
CD209, CD35, CD36 
Variable (Bucala et al., 1994) 
Fc receptors   
CD16, CD32a, CD32b, CD32c Moderate (Bucala et al., 1994) 
Chemokine receptors   
CCR2, CCR5, CCR4, CCR7, CCR9, 
CXCR1, CXCR4, CXC3R1 
Moderate 
(Mehrad et al., 2007; 
Pilling et al., 2009) 
Antigen Presentation   
CD80, CD86, MHCI, MCHII Low (Chesney et al., 1997) 
Extracellular matrix   
Collagen-I/III/IV, vimentin, 
tenascin 
Low 
(Bucala et al., 1994; 
Schmidt et al., 2003; 
Pilling et al., 2009) 
Fibronectin, -SMA Variable 
(Bianchetti et al., 2011; 
Bucala et al., 1994; 
Schmidt et al., 2003; 
Pilling et al., 2009) 
Collagen V Moderate (Bianchetti et al., 2011) 
Glycosaminoglycans   
Perlecan, Veriscan, Hyaluronan Moderate (Bianchetti et al., 2011) 
Decorin Low  
Miscellaneous   
Semaphorin 7a Low (Mathai et al., 2010) 
CD115 None (Pilling et al., 2009) 
Thy1.1 Low (Douglas et al., 2009) 
CD105 Low (Pilling et al., 2009) 
Table 1. Fibrocyte Marker Expression 
For example, human fibrocytes respond to Interleukin-1 beta (IL-1ǃ) by increasing secretion 
of proinflammatory mediators such as Interleukin-6 (IL-6), Interleukin-8 (IL-8), and 
Chemokine (C-C motif) ligand 21. Porcine fibrocytes respond to innate immune stimulation 
adopting certain properties of antigen presenting cells via their expression of Major 
Histocompatibility Complex I and II, CD80 and CD86 (Balmelli et al., 2007). This function is 
also seen in human fibrocytes (Chesney et al., 1997). In addition to these pro-inflammatory 
effects, fibrocytes also secrete paracrine factors such as Interleukin-10 (Chesney et al., 1998), 
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TGF-ǃ1, and platelet-derived growth factor (PDGF), which are expected to dampen 
inflammation and induce repair and angiogenesis. 
This latter function is augmented via their secretion of matrix metalloproteinases (MMPs), 
vascular endothelial growth factor (VEGF), PDGF-A, hepatocyte growth factor (HGF), 
granulocyte–macrophage colony stimulating factor (GM-CSF), basic fibroblast growth factor 
(b-FGF), IL-8 and IL-1ǃ (Hartlapp et al., 2001). Via their expression of Semaphorin 7a, 
fibrocytes may directly activate macrophages and dendritic cells (Suzuki et al., 2007) and 
negatively regulate T cell responses (Czopik et al., 2006). This array of functions suggest that 
fibrocytes are a highly plastic cell population that may significantly promote the aberrant 
immune response and tissue remodeling seen in scleroderma. In order to further explore the 
factors promoting fibrocyte accumulation in the blood and lungs of patients with SSc-ILD, 
we performed the following set of translational studies. 
3. Materials and methods 
TGFβ1 transgenic mice: All mouse experiments were approved by the Yale School of 
Medicine Institutional Animal Care and Use Committee. The CC10-tTS-rtTA- TGF-ǃ1 
transgenic mice used in this study have been described (Lee et al., 2004). The Sema-7a null 
mice were provided by Dr. Alex Kolodkin (Johns Hopkins) and have been described 
previously (Pasterkamp et al., 2003). 
Doxycycline Administration: Eight-to-10 week old CC10-tTS-rtTA- TGF-ǃ1 transgene 
positive (Tg+) or transgene negative (Tg-) mice with the Sema-7a locus null or intact were 
given doxycycline 0.5mg/ml in their drinking water for up to 2 weeks. 
Bone marrow transplantation: Mice were prepared for bone marrow transplantation using 
400 cGy total body irradiation. Bone marrow harvest, preparation, and injection were 
performed as previously described (Herzog et al., 2006). 
β1 integrin blocking antibodies: TGF-ǃ1 Tg+ and Tg- mice with an intact Sema-7a locus 
were injected with 125 μg of a neutralizing anti-ǃ1 integrin antibody or isotype control (both 
from Biolegend) as previously described (Bungartz et al., 2006). 
Lung inflammation: Euthanasia and bronchoalveolar lavage were performed as previously 
described (Lee et al., 2004). Lung inflammation was assessed via bronchoalveolar lavage 
(BAL) samples as described previously (Lee et al., 2004). 
Collagen assessment: Total left lung collagen was measured using the Sircol Assay 
following the manufacturer’s protocol (Biocolour, Ireland). 
Flow cytometry for fibrocytes: Flow cytometry was performed as previously described 
(Mathai et al., 2010). 
Histologic analysis: Formalin-fixed and paraffin-embedded lung sections were stained with 
hematoxylin and eosin to assess gross morphology or Mallory's trichrome stains to visualize 
collagen deposition. 
mRNA analyses: Total RNA was obtained using TRIzol reagent (Invitrogen) according to 
the manufacturer's instructions. Primers specific for human Sema-7a, ǃ1 integrin subunit, 
Plexin C1 and GAPDH, and murine ǃ1 integrin subunit, Plexin C1, and ǃ-actin were 
purchased from Superarray Bioscience. Gene expression levels were quantified using real 
time RT-PCR (Applied Biosystems), according to the manufacturer's protocols and 
normalized to GAPDH or ǃ-actin mRNA. 
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Human cell isolation and culture: All studies were performed with HIC approval and 
written informed consent at Yale University School of Medicine. Cells were cultured as 
previously described (Mathai et al., 2010). 
TUNEL: TUNEL was performed as previously described (Murray et al., 2011). 
Caspase activation: Detection of caspase cleavage and activation using 
immunohistochemistry was performed as previously described (Lee et al., 2004). 
Annexin V: Flow cytometric assessment of annexin V externalization was performed via 
flow cytometry as previously described (Lee et al., 2004). 
Statistics: Normally distributed data were expressed as means ± SEM and assessed for 
significance by Student's t test or ANOVA as appropriate. Data that were not normally 
distributed were assessed for significance using the Mann-Whitney U test. 
4. Results 
4.1 Circulating fibrocytes are elevated in SSc-ILD 
In order to determine whether fibrocytes are found with increased frequency in the 
circulation of patients with SSc-ILD, peripheral blood mononuclear cells were obtained from 
a cohort of patients with SSc-ILD (n=12) and normal controls (n= 27) and assessed for 
fibrocytes based on the coexpression of CD45 and Pro-Collagen-Iǂ. This double positive 
population was seen in both cohorts, and while overall percentages of fibrocytes were not 
increased in the SSc-ILD subjects, total quantities of collagen producing leukocytes, were 
increased by 79% in the SSc-ILD cohort compared to controls (Figure 1, p<0.05) (Mathai et 
al., 2010) and reflected impairments in ventilatory function as measured by the percent-
predicted forced vital capacity (FVC) (E. Herzog, unpublished data). These cells displayed 
enriched expression of CD34 and in some cases also expressed CD14, indicating both their 
multipotent potential as well as their monocytic origin. Since this work was first published 
these results have been confirmed by at least one other group (Tourkina et al., 2011) 
indicating the reproducibility of the fibrocyte assay in this patient population. 
4.2 Circulating fibrocytes exist in a profibrotic milieu 
In order to determine the immunologic milieu in which these fibrocytes exist, further 
phenotyping of these subjects was performed. Further analysis of circulating monocytes 
from these individuals found them to be skewed towards an alternatively activated, 
profibrotic phenotype as evidenced by a propensity to adopt both CD163 expression and 
CCL18 secretion when stimulated with LPS. Multianalyte ELISA of plasma from these 
patients demonstrated increased concentrations of profibrotic cytokines and chemokines 
such as IL10, TNF-a, and IL-1 RA (Mathai et al., 2010). Many of the mediators are 
commonly associated with alternatively activated macrophages (or “M2”) leading to some 
speculation that fibrocytes may simply represent an intermediate population in the 
terminal differentiation of profibrotic macrophages (Reilkoff et al., 2011). Another 
interesting aspect of these data were that similar (though not identical) results were seen 
in a cohort of aged but otherwise healthy individuals, leading to the speculation that the 
presence of fibrocytes may represent a previously unrecognized form of 
immunosenscence in patients with SSc-ILD. The presence of increased fibrocytes in the 
senescence associated mouse model of accelerated aging supports this hypothesis though 
further work is required to prove its validity. 
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Fig. 1. Comparison of CD45+/pro-Col-Iǂ+ percentages (left axis) and quantities (right axis) 
in normal (n=27, gray bar) and SSc-ILD subjects (n=12, black bar). CD45+/pro-Col-Iǂ+ cell 
quantities, but not percentages, are increased in SSc-ILD. (Mathai et al., 2010) 
4.3 Local apoptosis regulates fibrocyte accumulation 
While it has long been noted that fibrocytes arise in the setting of profibrotic stimuli such as 
TGF-ǃ1, the local factors regulating the monocyte to fibrocyte transition have remained 
largely unexplored. Several of our recent studies, however, lend insight into these processes. 
One outstanding question in this area has been the relationship between injury and 
fibrocytes. A requirement for apoptosis in the intrapulmonary accumulation of fibrocytes 
was recently explored in a model of lung fibrosis caused by inducible, lung-specific 
overexpression of the bioactive form of the human TGF-ǃ1 gene. These mice develop an 
epithelial injury response dominated by apoptosis that peaks at 48 hours following 
doxycycline administration. Shortly thereafter a dense monocytic infiltrate arises that is 
predominantly composed of CD206+ M2 macrophages (Murray et al., 2011). These 
macrophages persist, and are required for the induction of activated myofibroblast 
development and the induction of a robust accumulation of ECM products and fibrosis that 
is evident by between 10-14 days of doxycycline exposure. It is not until fibrosis is relatively 
well established that intrapulmonary fibrocytes appear in this model. Because scleroderma 
related lung disease is characterized by heightened responsiveness to autocrine TGF-ǃ1 
signaling via both canonical and non-canonical pathways (Sargent et al., 2011), this model is 
an ideal tool to study the pathogenesis of SSc-ILD. 
The role of apoptosis in fibrocyte accumulation was tested in this model using a fairly 
straightforward approach. TGF-ǃ1 mice were randomized to receive systemic injections of 
the pan-caspase inhibitor Z-VAD/fmk or vehicle control. Reductions in apoptosis were 
confirmed at 48 hours by comparison of TUNEL staining and caspase 3 activation in Z-
VAD/fmk treated TGF-ǃ1 mice. Reductions in lung inflammation and fibrosis were noted at 
day 14. Fibrocytes, defined via classical flow cytometric criteria by CD45 and Pro-Collagen-
Iǂ co-expression, were reduced by nearly 10-fold at the 14 day time point (Figure 2a, 
p<0.001). The human relevance of these findings was supported by the finding that SSc-ILD 
lungs contain increased levels of CD45+ collagen-producing cells (Peng et al., 2011), and that 
these lungs contain increased numbers of TUNEL+ve apoptotic cells. Additionally CD14+ 
monocytes cultured in the presence of Z/VAD-fmk fail to adopt the spindle-shaped, 
collagen expressing phenotype that characterizes fibrocytes (Figure 2c,d, p<0.001). Thus, 
from these studies it is reasonable to conclude that fibrocytes arise in response to apoptotic 
stimuli. 
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In addition to the information regarding the precise relationship between apoptosis and 
fibrocytes, these studies also allowed new insight into the relationship between M2 
macrophages and fibrocytes. Recent literature has suggested that macrophages are capable 
of expressing collagen (Pilling et al., 2009) and thus the CD45/Col-Iǂ signature may not 
sufficiently differentiate between fibrocytes and alternatively activated (M2) macrophages. 
Prior studies have demonstrated that alveolar macrophages obtained from patients with 
SSc-ILD demonstrate a distinct M2 profibrotic phenotype and that alternatively activated 
macrophages (M2) in part regulate fibrosis (Atamas et al., 2003). Thus it could be argued 
that the reduction in CD45/Col-Iǂ cells previously noted could be related to changes in 
alternatively activated macrophages quantities or rather that M2 macrophages regulate the 
appearance of CD45/Col-Iǂ cells. However, in our studies caspase inhibition demonstrated 
no significant differences in numbers of CD206/MRC positive cells between sham treated 
and ZVAD treated mice, nor was there a significant difference in M2 related genes 
CD206/MRC and MSR-1 using quantitative RT-PCR between the two cohorts (Peng et al., 
2011). Likewise, in a separate set of studies in which M2 macrophages were removed by 
intratracheal instillation of liposomal clodronate, removal of M2 macrophages did not affect 
intrapulmonary fibrocyte content. Curiously, fibrocytes persisted despite profound 
attenuation of collagen deposition (Murray et al., 2011). When viewed in combination, these 
studies suggest that fibrocytes and M2 macrophages are regulated independently of each 
other and that each cell type exert separate, but complementary, effects on TGF-ǃ1 
fibrogenesis. 
 
 
Fig. 2. Caspase inhibition administration attenuates apoptosis and collagen production in 
cultured human monocytes. (a) Z-VAD/fmk reduces CD45+Col-Iǂ1+ cells in TGF-ǃ1 Tg+ 
mice. (b) Treatment with ZVAD/fmk attenuates collagen production in samples from all 
groups. (c,d) CT-ILD cultured monocytes fail to adopt a spindle shaped phenotype when 
treated with Z-VAD/fmk. (Peng et al., 2011) 
www.intechopen.com
 
Fibrocytes in Scleroderma Lung Fibrosis 
 
125 
4.4 Role of semaphorin 7a in fibrocyte outgrowth 
Previous studies have indicated that fibrocyte biology is induced by exposure to soluble 
factors such as Th2 cytokines and activation of several chemokine pathways including 
CXCL12, MCP-1, and CCL21. However, the TGF-ǃ1 specific factors controlling their 
differentiation has remained less clear. Because SSc-ILD is associated with a unique 
“signature” of TGF-ǃ1 responsiveness (Sargent et al., 2010) we explored the role of TGF-ǃ1 
signaling in fibrocyte accumulation. Because the monocyte-driven effects on fibrosis appear 
to be SMAD2/3 independent (Murray et al., 2011), we explored noncanonical TGF-ǃ1 
pathways in this model. One such pathway is controlled by activation of Semaphorin 7a. 
Semaphorins (Semas) are a family of highly conserved, secreted or membrane-associated 
proteins, expressed on stroma as well as nerve, myeloid and lymphoid cells. Originally 
discovered as axonal guidance proteins (Pasterkamp et al., 2003), eight classes of 
Semaphorins have since been discovered with Semas 3-7 subsequently being found to 
participate in a variety of processes related to organogenesis, angiogenesis, apoptosis, 
neoplasia and immune regulation (Pasterkamp & Kolodkin, 2003). Semaphorin 7a (Sema 
7a), also called CDw108, is a GPI-anchored membrane protein that by signaling through its 
two main receptors, Plexin C1 and ǃ1 integrin, contributes to inflammation (Suzuki et al., 
2007), modulation of T cell function (Czopik et al., 2006), and TGF-ǃ1 induced pulmonary 
fibrosis (Kang et al., 2007). However, until recently a role for Sema 7a in fibrocyte 
development had not been explored. 
In order to explore this question we crossed TGF-ǃ1 mice with mice harboring null 
mutations of the Sema 7a gene. In addition to effects on lung fibrosis and remodeling, which 
had been described previously, we found that fibrosis (quantified via sircol analysis) and 
fibrocytes were markedly reduced in the TGF-ǃ1 mice that lacked Sema 7a (Figure 3a, p < 
0.001). These effects were explored further in bone marrow chimera experiments in which 
TGF-ǃ1 mice were created in which Sema 7a expression was restricted to lung stroma or to 
bone marrow derived cells. Lung restricted Sema 7a expression in TGF-ǃ1 mice revealed a 
modest but insignificant reduction in fibrosis and fibrocyte content. However in the TGF-ǃ1 
x Sema 7a null cohort of mice where Sema 7a expression was restored on bone marrow 
derived cells these mice developed increased fibrosis and fibrocytes (Gan et al., 2011). These 
studies reveal that Sema 7a expressing bone marrow derived cells are sufficient, but not 
necessary, for the development of fibrosis and fibrocyte accumulation in the TGF-ǃ1 
exposed murine lung. 
In order to explore the human relevance of these findings we interrogated the relationship 
between Sema 7a and fibrocyte biology in a second cohort of patients with SSc-ILD. In these 
studies, enhanced expression of Sema 7a and its two known receptors (ǃ1 integrin and 
Plexin C1) were detected in peripheral blood mononuclear cells (PBMCs) from patients with 
SSc-ILD, but not SSc only, indicating that the Sema 7a axis may be unique to patients with 
interstitial lung involvement. Flow cytometric analysis revealed that the increased 
expression of Sema 7a appeared to be related to augmented cell surface on fibrocytes and 
CD19+ lymphocytes. In contrast, Sema 7a receptors ǃ1 integrin and Plexin C1 were located 
on CD14+ monocytes (Gan et al., 2011). This led to speculation that exogenous ligation of 
these receptors by Sema 7a (either membrane bound or secreted) controls the monocyte to 
fibrocyte transition in this patient population. 
The validity of this hypothesis was then tested in ex vivo studies of fibrocytes using standard, 
serum containing conditions. Specifically, monocytes from scleroderma subjects or controls 
were cultured in the presence or absence of recombinant Sema 7a stimulation for 14 days. 
These cultures were further exposed to Sema 7a receptor blockade of ǃ1 integrin or Plexin C1. 
In normal controls, Sema 7a exposure led to enhanced fibrocyte outgrowth, however, in 
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monocytes obtained from individuals with SSc-ILD, stimulation with Sema 7a had little effect 
on the already markedly enhanced fibrocyte numbers that exist at baseline in these cultures. In 
both groups these results were attenuated by ǃ1 integrin blockade and enhanced by Plexin C1 
blockade (Figure 3 c,d). When viewed in combination it appears that Sema 7a controls the 
monocyte to fibrocyte transition in a ǃ1 integrin dependent manner that is opposed by Plexin 
C1 (Gan et al., 2011). Thus, the increased Plexin C1 gene expression seen in the SSc-ILD 
patients may represent a novel counter-regulatory response and a new target for therapy. 
 
 
Fig. 3. (a) Total left lung collagen in wild type mice (white bar) and TFG-ǃ1 Tg+ mice (black 
bar). Left: Sema-7a locus intact. Right: Sema-7a locus deleted. (b) Compared to TGF-ǃ1XWT 
mice, lungs from TGF-ǃ1XSema-7a null mice contain significantly decreased quantities of 
CD45+Col-Iǂ+ cells. White bar: WT. Black bar: TGF-ǃ1 Tg+ mouse. (c) Sema-7a stimulated 
PBMCs show increased fibrocyte differentiation (white, left comparisons). In contrast, SSc-
ILD subjects show increased fibrocyte outgrowth at baseline (black, left comparisons) with 
no response to exogenous Sema stimulation but pronounced reduction via 
immunoneutralization of the ǃ1 integrin subunit (right comparisons). (d) Inhibition of 
Plexin C1 promotes fibrocyte differentiation in Sema-7a stimulated monocytes from control 
and SSc-ILD subjects as well as in unstimulated SSc-ILD monocytes. (Gan et al., 2011) 
5. Conclusion 
Fibrocytes have been implicated in a wide array of human autoimmune and inflammatory 
diseases since their identification 17 years ago. Human and animal studies have confirmed 
elevated levels of these mesenchymal progenitor cells in blood and tissue during fibrotic 
disease states. Animal models have also revealed the fibrocytes’ complex role in the repair 
and remodeling of injured tissue, which includes antigen presentation, ECM and cytokine 
production, promotion of angiogenesis and differentiation to myofibroblasts. Because of 
their role in the maintenance and homeostasis of connective tissue, they have emerged as a 
cell of interest in scleroderma, and specifically SSc-ILD. Our work in these patients revealed 
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a significant association between circulating fibrocytes and SSc-ILD. Targeting these cells, 
and their relationship with such regulatory factors as TGF-ǃ1, apoptosis, and Semaphorin 7a 
may ultimately lead to the discovery of new biomarkers and perhaps even novel therapeutic 
targets in SSc-ILD. 
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